Review Article
Progress in Mesenchymal Stem Cell Therapy for Ischemic Stroke
Table 2
Gene transfection in the treatment of IS with MSCs.
| Transfected gene | Transfected vector | Cell type | Dose | Transplantation route | Administration time | Outcome (compared with normal MSCs) | Reference |
| BDNF | Adenovirus | hBM-MSCs | | Intracerebral injection | 24 hours after MCAO | Fewer apoptotic cells; smaller infarcted volume; improvement of neurological function | [45] | GDNF | Adenovirus | hBM-MSCs | | Intravenous injection | 3 hours after MCAO | Smaller infarcted volume; higher function recovery | [48] | HGF | Herpes sim-plex virus type-1 | BM-MSCs | | Intracerebral injection | 2 or 24 hours after MCAO | Fewer apoptotic cells; smaller infarcted volume; higher function recovery | [208] | PIGF | Adenovirus | hBM-MSCs | | Intravenous injection | 3 hours after MCAO | More angiogenesis; smaller infarcted volume; higher function recovery | [60] | FGF1 | pCMV6-entry vector | AD-MSCs | | Intravenous injection | 0.5 hour after MCAO | Fewer apoptotic cells; smaller infarcted volume; higher function recovery | [61] | Ang; VEGF; Ang+ VEGF | Adenovirus | hBM-MSCs | | Intravenous injection | 6 hours after MCAO | Ang/Ang+ VEGF: more angiogenesis; smaller infarcted volume; higher function recovery. VEGF: infarct size increased; function deteriorated | [56] | VEGF | Adenovirus | BM-MSCs | | Intracerebral injection | 24 hours after MCAO | More angiogenesis; smaller infarcted volume; higher function recovery | [170] | Hif-1α | Lentivirus | BM-MSCs | | Intracerebral injection | 24 hours after MCAO | Lower level of proinflammatory cytokines; higher level of neurotrophins; smaller infarcted volume; higher function recovery | [169] | TSP4 | Lentivirus | BM-MSCs | | Intravenous injection | 3 hours after MCAO | Higher levels of Ang-1 and vWF; more angiogenesis; higher function recovery | [209] | IL-10 | Adeno-associated virus | hBM-MSCs | | Intravenous injection | 0 or 3 hours after MCAO | Lower level of proinflammatory cytokines and microglial activation; smaller infarcted volume; higher function recovery | [162] | CCR2 | Lentivirus | BM-MSCs | | Intravenous injection | 24 hours after MCAO | More homing; less BBB leakage; higher function recovery | [159] | CCL2 | None | hUC-MSCs | | Intravenous injection | 1 and 4 days after MCAO | More homing; more angiogenesis and neurogenesis; less neuroinflammation; smaller infarcted volume; higher function recovery | [160] | Ngn1 | Retrovirus | hBM-MSCs | | Intra-arterial injection | 2 hours after MCAO | More homing; fewer apoptotic cells; less neuroinflammation; higher function recovery | [161] | Noggin | Adenovirus | BM-MSCs | | Intravenous injection | 6 hours after MCAO | More neurogenesis; smaller infarcted volume; higher function recovery | [164] |
|
|